Company: MDCXW
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001062993-25-016838
Chunk: 115

Company: Medicus Pharma Ltd.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 115
---
 Offering"). The Company issued 2,260,000 units at a price of $3.10 per unit.  Each unit consisted of one common share of the Company and one warrant to purchase one common share (the "June 2030 Warrants").  The June 2030 Warrants have an exercise price of $3.10 per share and will expire on June 2, 2030.  As of September 30, 2025, none of the June 2030 Warrants have been exercised.

The Company incurred equity issuance costs of $653,504 during the period ended September 30, 2025.

Results of Operations

The following table outlines our statements of loss and comprehensive loss for the three and nine months ended September 30, 2025 and 2024:

  Three months endedSeptember 30,     Nine months ended September30,      2025  2024     2025  2024      $  $  Change   $  $  Change General and administrative 5,024,082  1,770,116  3,253,966  12,720,666  5,432,773  7,287,893 Research and development 1,684,783  564,145  1,120,638  5,130,561  2,162,680  2,967,881 Acquired in-process research and development (IPR&D) - Teverelix 8,717,475  -  8,717,475  8,717,475  -  8,717,475 Total operating expenses 15,426,340  2,334,261  13,092,079  26,568,702  7,595,453  18,973,249 Loss from operations (15,426,340) (2,334,261) (13,092,079) (26,568,702) (7,595,453) (18,973,249)Other income (expense):                  Interest income (expense) 11,572  55,514  (43,942) 75,442  (23,511) 98,953 Loss on SEPA settlements (157,721) -